NCT03674463View on ClinicalTrials.gov

LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

PHASE1UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Refractory or Relapsed Multiple Myeloma
Interventions
DRUG

LCAR-B4822M CAR-T Cell Immunotherapy

Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the LCAR-B4822M CAR-T Cell Immunotherapy by intravenous injection.

Trial Locations (1)

710000

Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an

Sponsors
All Listed Sponsors
collaborator

Nanjing Legend Biotech Co.

INDUSTRY

lead

Second Affiliated Hospital of Xi'an Jiaotong University

OTHER